La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Asia Vital Components Croissance future
Future contrôle des critères 6/6
Asia Vital Components devrait augmenter ses bénéfices et son chiffre d'affaires de 28.5% et de 23.2% par an respectivement. Le BPA devrait croître de de 28.6% par an. Le rendement des capitaux propres devrait être 34.7% dans 3 ans.
Informations clés
29.9%
Taux de croissance des bénéfices
30.0%
Taux de croissance du BPA
Tech croissance des bénéfices | 16.3% |
Taux de croissance des recettes | 23.5% |
Rendement futur des capitaux propres | 35.0% |
Couverture par les analystes | Good |
Dernière mise à jour | 20 Sep 2024 |
Mises à jour récentes de la croissance future
Analysts Are Updating Their Asia Vital Components Co., Ltd. (TWSE:3017) Estimates After Its First-Quarter Results
Aug 13Asia Vital Components Co., Ltd. (TWSE:3017) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 17Recent updates
Is Asia Vital Components (TWSE:3017) A Risky Investment?
Sep 28Analysts Are Updating Their Asia Vital Components Co., Ltd. (TWSE:3017) Estimates After Its First-Quarter Results
Aug 13Asia Vital Components Co., Ltd.'s (TWSE:3017) Stock Retreats 30% But Earnings Haven't Escaped The Attention Of Investors
Aug 06Is Asia Vital Components Co., Ltd. (TWSE:3017) Worth NT$634 Based On Its Intrinsic Value?
Jul 22Asia Vital Components (TWSE:3017) Is Investing Its Capital With Increasing Efficiency
Jul 04Asia Vital Components Co., Ltd.'s (TWSE:3017) P/E Is Still On The Mark Following 30% Share Price Bounce
May 29We Think Asia Vital Components (TWSE:3017) Can Manage Its Debt With Ease
May 21Do Asia Vital Components' (TWSE:3017) Earnings Warrant Your Attention?
Apr 17A Look At The Intrinsic Value Of Asia Vital Components Co., Ltd. (TWSE:3017)
Apr 03Impressive Earnings May Not Tell The Whole Story For Asia Vital Components (TWSE:3017)
Mar 21Asia Vital Components Co., Ltd. (TWSE:3017) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 17Market Participants Recognise Asia Vital Components Co., Ltd.'s (TWSE:3017) Earnings Pushing Shares 29% Higher
Feb 26Is Now The Time To Look At Buying Asia Vital Components Co., Ltd. (TPE:3017)?
Apr 23Does Asia Vital Components (TPE:3017) Have A Healthy Balance Sheet?
Apr 08Asia Vital Components Co., Ltd.'s (TPE:3017) Attractive Combination: Does It Earn A Place In Your Dividend Portfolio?
Mar 21Will The ROCE Trend At Asia Vital Components (TPE:3017) Continue?
Feb 16Asia Vital Components Co., Ltd.'s (TPE:3017) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 01Did You Participate In Any Of Asia Vital Components' (TPE:3017) Fantastic 223% Return ?
Jan 17Asia Vital Components (TPE:3017) Seems To Use Debt Quite Sensibly
Jan 02Why Asia Vital Components Co., Ltd. (TPE:3017) Is A Dividend Rockstar
Dec 20Is Now An Opportune Moment To Examine Asia Vital Components Co., Ltd. (TPE:3017)?
Dec 07Is There More To The Story Than Asia Vital Components's (TPE:3017) Earnings Growth?
Nov 24Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 112,846 | 13,742 | 12,553 | 12,723 | 6 |
12/31/2025 | 94,810 | 11,218 | 9,899 | 13,645 | 13 |
12/31/2024 | 71,133 | 7,986 | 5,757 | 9,274 | 11 |
6/30/2024 | 64,281 | 6,608 | 10,463 | 13,535 | N/A |
3/31/2024 | 62,669 | 5,862 | 9,416 | 12,594 | N/A |
12/31/2023 | 59,194 | 5,305 | 6,556 | 10,324 | N/A |
9/30/2023 | 57,251 | 4,715 | 4,935 | 8,918 | N/A |
6/30/2023 | 56,365 | 4,528 | 3,682 | 8,120 | N/A |
3/31/2023 | 55,258 | 4,423 | 4,358 | 8,612 | N/A |
12/31/2022 | 56,017 | 4,162 | 5,135 | 8,840 | N/A |
9/30/2022 | 53,452 | 3,792 | 3,312 | 6,298 | N/A |
6/30/2022 | 50,342 | 3,407 | 2,133 | 4,482 | N/A |
3/31/2022 | 49,327 | 3,106 | 1,774 | 3,727 | N/A |
12/31/2021 | 47,333 | 2,901 | 1,213 | 2,841 | N/A |
9/30/2021 | 45,646 | 2,704 | 2,026 | 4,261 | N/A |
6/30/2021 | 43,922 | 2,490 | 2,364 | 4,768 | N/A |
3/31/2021 | 42,778 | 2,262 | 1,029 | 3,626 | N/A |
12/31/2020 | 39,666 | 1,916 | 2,404 | 4,870 | N/A |
9/30/2020 | 39,361 | 1,690 | 2,950 | 4,833 | N/A |
6/30/2020 | 39,228 | 1,308 | 1,491 | 3,318 | N/A |
3/31/2020 | 37,107 | 972 | 2,185 | 3,816 | N/A |
12/31/2019 | 36,534 | 958 | 757 | 2,458 | N/A |
9/30/2019 | 34,258 | 871 | -648 | 971 | N/A |
6/30/2019 | 31,962 | 800 | 327 | 1,905 | N/A |
3/31/2019 | 29,482 | 747 | 274 | 1,719 | N/A |
12/31/2018 | 29,067 | 711 | -723 | 971 | N/A |
9/30/2018 | 28,673 | 717 | 122 | 1,635 | N/A |
6/30/2018 | 27,873 | 776 | -364 | 940 | N/A |
3/31/2018 | 27,178 | 811 | N/A | 1,609 | N/A |
12/31/2017 | 27,109 | 887 | N/A | 1,806 | N/A |
9/30/2017 | 26,750 | 930 | N/A | 1,684 | N/A |
6/30/2017 | 26,496 | 898 | N/A | 1,961 | N/A |
3/31/2017 | 26,528 | 869 | N/A | 1,230 | N/A |
12/31/2016 | 26,504 | 860 | N/A | 2,154 | N/A |
9/30/2016 | 26,040 | 826 | N/A | 3,340 | N/A |
6/30/2016 | 26,312 | 829 | N/A | 3,133 | N/A |
3/31/2016 | 26,194 | 797 | N/A | 3,080 | N/A |
12/31/2015 | 25,675 | 741 | N/A | 2,493 | N/A |
9/30/2015 | 25,023 | 681 | N/A | 1,124 | N/A |
6/30/2015 | 24,317 | 822 | N/A | 1,898 | N/A |
3/31/2015 | 24,336 | 820 | N/A | 2,021 | N/A |
12/31/2014 | 24,047 | 729 | N/A | 1,962 | N/A |
9/30/2014 | 23,739 | 640 | N/A | 2,369 | N/A |
6/30/2014 | 22,767 | 355 | N/A | 913 | N/A |
3/31/2014 | 21,397 | 282 | N/A | 1,984 | N/A |
12/31/2013 | 19,990 | 246 | N/A | 1,505 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 3017 ( 28.5% par an) est supérieure au taux d'épargne ( 1% ).
Bénéfices vs marché: Les bénéfices de 3017 ( 28.5% par an) devraient croître plus rapidement que le marché TW ( 18.7% par an).
Croissance élevée des bénéfices: Les bénéfices de 3017 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 3017 ( 23.2% par an) devrait croître plus rapidement que le marché TW ( 11.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 3017 ( 23.2% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 3017 devrait être élevé dans 3 ans ( 34.7 %)